Tiago Reis Marques net worth and biography

Tiago Marques Biography and Net Worth

Chief Executive Officer and Director of Pasithea Therapeutics

Dr. Tiago Reis Marques has served on our board of directors and as Chief Executive Officer since August 2020. He is a senior clinical fellow at Imperial College London and a lecturer at the IoPPN, King’s College London. IoPPN is ranked second in the world for psychology and psychiatry by US News and Best Global Universities and is home to one of the world’s largest centers for neuroscience research. Dr. Marques is also a psychiatrist at Maudsley Hospital. His research focuses on topics including the mechanism of action of psychiatric medication and novel treatment targets. During his career, he has obtained multiple awards for his research. Dr. Marques is an author or co-author of more than 100 scientific publications in peer-reviewed journals in psychiatry and neuroscience, has co-authored international treatment guidelines and written book chapters, including in the leading book in the field, “Neurobiology of Mental Illness.”

What is Tiago Reis Marques' net worth?: The estimated net worth of Tiago Reis Marques is at least $36.30 thousand as of November 28th, 2025. Dr. Marques owns 73,334 shares of Pasithea Therapeutics stock worth more than $36,300 as of October 2nd. This net worth estimate does not reflect any other investments that Dr. Marques may own. Learn More about Tiago Reis Marques' net worth.
How do I contact Tiago Reis Marques?: The corporate mailing address for Dr. Marques and other Pasithea Therapeutics executives is 1111 Lincoln Road Suite 500, Miami Beach FL, 33139. Pasithea Therapeutics can also be reached via phone at 702-514-4174 and via email at [email protected]. Learn More on Tiago Reis Marques' contact information.
Has Tiago Reis Marques been buying or selling shares of Pasithea Therapeutics?: Tiago Reis Marques has not been actively trading shares of Pasithea Therapeutics during the past quarter. Most recently, on Friday, November 28th, Tiago Reis Marques bought 33,333 shares of Pasithea Therapeutics stock. The stock was acquired at an average cost of $0.75 per share, with a total value of $24,999.75. Following the completion of the transaction, the chief executive officer now directly owns 73,334 shares of the company's stock, valued at $55,000.50. Learn More on Tiago Reis Marques' trading history.
Who are Pasithea Therapeutics' active insiders?: Pasithea Therapeutics' insider roster includes Simon Dumesnil (Director), Tiago Marques (Chief Executive Officer and Director), and Lawrence Steinman (Director). Learn More on Pasithea Therapeutics' active insiders.
Are insiders buying or selling shares of Pasithea Therapeutics?: In the last twelve months, Pasithea Therapeutics insiders bought shares 3 times. They purchased a total of 199,999 shares worth more than $149,999.25. The most recent insider tranaction occured on November, 28th when CEO Tiago Reis Marques bought 33,333 shares worth more than $24,999.75. Insiders at Pasithea Therapeutics own 1.5% of the company. Learn More about insider trades at Pasithea Therapeutics.
Information on this page was last updated on 11/28/2025.

Tiago Reis Marques Insider Trading History at Pasithea Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/28/2025	Buy	33,333	$0.75	$24,999.75	73,334
5/12/2025	Sell	960	$0.82	$787.20	40,001

Tiago Reis Marques Buying and Selling Activity at Pasithea Therapeutics

Pasithea Therapeutics Company Overview

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Today's Range

Now: $0.48

$0.47

$0.51

50 Day Range

MA: $0.51

$0.44

$0.60

2 Week Range

Now: $0.48

$0.28

$2.06

Volume

48,874 shs

Average Volume

459,445 shs

Market Capitalization

$16.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.34